Reading CCEL? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CCEL free→Reading CCEL? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CCEL free→QuarterlyIQ Insights · CCEL
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 6, 2026, Cryo-Cell International, Inc. (the "Company”) received a written notice from NYSE Regulation stating that it had accepted the Company’s plan to regain compliance with the continued listing standards of the NYSE American LLC ("NYSE American"). As previously disclosed, the Company submitted a compliance plan to NYSE American on April 8, 2026. NYSE Regulation accepted the plan and…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On March 9, 2026, Cryo-Cell International, Inc. (“Cryo-Cell”) received a written notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003 (a) of the NYSE American Company Guide. The Notice has no immediate effect on the listing or trading of the Company’s common stock, which wi…
Other Events. Cryo-Cell International, Inc. ("Cryo-Cell") will not declare a quarterly cash dividend for the fourth quarter of fiscal 2025. Cryo-Cell may or may not pay a dividend in future periods, and any future decisions regarding dividend declarations will be based on a variety of factors, including financial performance, capital requirements, and strategic priorities. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this repor…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant (a) The information included in
Entry into a Material Definitive Agreement. As previously disclosed, on July 18, 2022, Cryo-Cell International, Inc. (the “Company”) entered into a Credit Agreement (“Credit Agreement”) with Susser Bank, a Texas state bank (“Susser”), as administrative agent on behalf of itself and the other lenders (collectively, the “Lenders”) for (i) an unsecured revolving line of credit in an aggregate principal amount of up to $10,000,000 (the “RCF”); and (ii) a term loan facility in an original principa…
Termination of a Material Definitive Agreement. Cryo-Cell International, Inc. (“Cryo-Cell”) has received from Duke University ("Duke") a notice of termination as of May 17, 2025, of the Patent and Technology License Agreement between Cryo-Cell and Duke dated effective as of February 23, 2021 (as amended, the "Duke License Agreement"). As previously disclosed, pursuant to the Duke License Agreement, Duke granted to Cryo-Cell an exclusive license to make, have made, use, import, offer for sale,…
Other Events. On May 7, 2025, as a result of the current economic environment and other capital allocation alternatives, the Board of Directors of Cryo-Cell International, Inc. ("Cryo-Cell") declared a reduced, quarterly cash dividend of $0.15 per share of common stock to be paid to its shareholders of record as of the close of business on May 21, 2025. The dividend is expected to be paid on May 30, 2025. .
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.